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Abstract
Background: Inflammatory bowel disease (IBD) is associated with a defective intestinal barrier and enhanced adaptive
immune responses against commensal microbiota. Immune responses against food antigens in IBD patients remain poorly
defined.
Methods: IgG and IgA specific for food and microfloral antigens (wheat and milk extracts; purified ovalbumin; Escherichia
coli and Bacteroides fragilis lysates; mannan from Saccharomyces cerevisiae) were analyzed by ELISA in the serum and feces
of patients with Crohn’s disease (CD; n = 52 for serum and n= 20 for feces), ulcerative colitis (UC; n = 29; n = 17), acute
gastroenteritis/colitis (AGE; n = 12; n = 9) as well as non-inflammatory controls (n = 61; n = 39).
Results: Serum anti-Saccharomyces cerevisiae antibodies (ASCA) and anti-B. fragilis IgG and IgA levels were increased in CD
patients whereas antibody (Ab) levels against E. coli and food antigens were not significantly different within the patient
groups and controls. Subgroup analysis revealed that CD patients with severe diseases defined by stricturing and
penetrating lesions have slightly higher anti-food and anti-microbial IgA levels whereas CD and UC patients with
arthropathy have decreased anti-food IgG levels. Treatment with anti-TNF-a Abs in CD patients was associated with
significantly decreased ASCA IgG and IgA and anti-E. coli IgG. In the feces specific IgG levels against all antigens were higher
in CD and AGE patients while specific IgA levels were higher in non-IBD patients. Anti-food IgG and IgA levels did not
correlate with food intolerance.
Summary: In contrast to anti-microbial Abs, we found only minor changes in serum anti-food Ab levels in specific
subgroups of IBD patients. Fecal Ab levels towards microbial and food antigens show distinct patterns in controls, CD and
UC patients.
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Introduction
Inflammatory bowel diseases (IBD) include a range of chronic,
immune-mediated inflammatory disorders of the gastrointestinal
system with fluctuating activity, most frequently represented by
Crohn’s disease (CD) or ulcerative colitis (UC). IBD has a
multifactorial etiology with hereditary and environmental triggers
and it has been associated with changes of the intestinal
microflora, defects in the gastrointestinal barrier with increased
transport of luminal contents into the tissue and a loss of immune
tolerance [1,2]. Consequently, specific adaptive immune responses
towards luminal antigens, in particular antigens of the commensal
microflora, are altered in IBD patients. Specific IgG and IgA
directed against a specific oligomannose epitope present on the cell
wall of the yeast Saccharomyces cerevisiae are strongly increased in
CD patients [3,4]. Anti-S. cerevisiae antibodies (ASCA) have been
established as serological markers aiding in diagnosis of CD [5]
and their titers correlate with the presence of ileal disease,
fibrostenotic and penetrating lesions, and risk for surgery [6].
Apart from ASCA, higher titers of circulating antibodies (Abs)
directed against multiple other microfloral antigens have been
found in IBD and in particular in CD patients. Those antigens are
for example E. coli outer-membrane porin C (anti-OmpC), the
Pseudomonas fluorescens-related protein (anti-I2), a protein found
in the flagella of bacteria, the CBir1 flagellin, and several other
glycan epitopes or bacterial flagella as well as less well defined
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antigen-mixtures such as cell lysates or membrane-associated
antigens of different Bacteroides spp., Klebsiella pneumoniae,
Enterococcus faecalis and Candida albicans [7–11].
Apart from microbial antigens, alimentary antigens are present
in high concentrations in the intestinal lumen. Considering the fact
that a defective intestinal barrier and a loss of immune tolerance
are pathogenic factors in IBD, it is possible that also food-specific
Ab levels are increased in IBD patients and may participate in
immune-mediated food intolerance in IBD patients. Classical
food-allergy is mediated by specific IgE antibodies and some
reports suggested that IgE-mediated food allergies are more
frequent in IBD patients [12–14]. However, specific IgE
antibodies were not analyzed in this study. Furthermore, food-
specific IgG and IgA antibodies are frequently found in patients as
well as healthy individuals and their contribution to food
intolerance remains a matter of debate [15,16]. The results of
the few studies analyzing food-specific IgG and IgA levels in the
serum of IBD patients and controls are not fully consistent. Lerner
et al. described increased IgG levels specific for cow’s milk proteins
in pediatric CD patients compared to UC patients and controls
[17]. Bentz et al. used a multiplex ELISA method to measure 271
specific anti-food IgG and found multiple increased food-specific
IgG levels in adult CD patients compared to controls [15]. In turn,
Lindberg et al. and Suzuki et al. did not detect elevated levels of
IgG and IgA directed against wheat, milk, or egg proteins in adult
CD patients. However, Lindberg et al. found enhanced anti-
gliadin IgA titers in adult UC patients and Suzuki et al. measured
increased levels of IgG specific for porcine pancreatic amylase, a
potential protease-resistant food derivative, in adult CD patients
[18,19].
As the majority of these smaller studies indicated rather elevated
levels of distinct IgG and IgA in IBD patients, we hypothesized
that chronic inflammation in the intestine is associated with the
loss of immunological tolerance towards luminal antigens leading
to pronounced specific Ab production. We therefore aimed at
comprehensively investigating local or systemic levels of anti-
microbial and anti-food Abs in IBD patients. For this purpose, we
analysed in parallel serum and fecal Abs specific for dietary and
microbial antigens in a cohort of IBD patients and controls. Our
results reveal that on the systemic level only Abs directed against
some microbial antigens are elevated in CD but not UC patients,
whereas anti-food Abs showed no general alterations in IBD
patients and only subtle changes in certain patient subgroups. In
contrast, fecal Ab levels towards different luminal antigens were
more uniformly regulated and showed distinct patterns in controls,
CD and UC patients.
Methods
Patients
Serum and stool samples were obtained from well characterized
IBD and control patients from the gastroenterology department at
the University Hospital Aachen. Characteristics of the patients are
depicted in Table S1 and S2. In addition to the IBD patients, three
control cohorts were investigated: (a) healthy volunteers, (b)
medical patients without infectious or non-infectious bowel
disease, (c) medical patients with acute gastroenteritis (AGE).
Pooled groups (a) and (b) served as non-inflammatory controls
(Con). Duration of symptoms in the AGE group was , 4 weeks.
Clinical disease activity of IBD patients was measured by the
Harvey Bradshaw Index (HBI) for CD and Colitis Activity Index
(CAI) for UC [20,21]. Disease phenotypes were classified
according to the Montreal classification [22] (Table S2).
Ethical considerations
Patients were included into the study upon providing written
informed consent. The study protocol was approved by the local
ethics committee and conducted in accordance with the ethical
standards laid down in the Declaration of Helsinki (ethics
committee of the University Hospital Aachen, RWTH-University,
Aachen, Germany, reference number EK 049/12).
Antigen preparation
Albumin from chicken egg white (ovalbumin; grade II), non-fat
dried milk powder, and purified mannan from S. cerevisiae were
purchased (Sigma). Antigens were diluted in carbonate buffer
pH 9.6. Commercially available wheat flour was mixed with
sodium acetate buffer (sodium acetate 6 mM; acetic acid 88 mM;
pH 3.8) according to a published protocol [23]. All antigens were
vigorously mixed for 1 h. E. coli K12 DH5a and B. fragilis
ATCC 25285 were grown over night in LB or thioglycolate
medium under aerobic or anaerobic culture conditions, respec-
tively. Cultures were washed by centrifugation (10.000 g, 5 min)
three times in carbonate buffer to remove medium proteins. Glass
beads with 0.3 mm diameter (Sigma) were added and tubes were
vigorously shaken at 2.850 rpm for 15 min on a disrupter
(Disruptor Genie, Scientific Industries, Inc.) in order to break
bacterial cell walls. All antigen mixtures (except for mannan) were
centrifuged for 20 min at 27.000 g to remove bacterial debris and
larger molecular complexes. Supernatants were passed through a
0.2 mm filter. Protein concentrations were measured using the
Bradford method. Protein yield of bacterial lysates were about
10% of the dry weight of total bacteria indicating sufficient
bacterial lysis.
Preparation of fecal samples
Fecal samples were diluted 1:5 (w/w) with fecal dilution buffer
(90 ml PBS, 10 ml 0.5 M EDTA pH 8, 10 mg soy bean trypsin
inhibitor [Sigma]; 666 ml 100 mM PMSF [Sigma; dissolved in
EtOH]). Samples were vigorously mixed and centrifuged at
10.000 g for 5 min. Supernatants were obtained and filtered
through a 0.2 mm filter.
ELISA
Microtitre plates (96 wells, Maxisorb, Nunc) were coated
overnight at 4uC with 50 ml of antigens in carbonate buffer
pH 9.6 The antigen concentrations were 100 mg/ml for mannan,
10 mg/ml for ovalbumin, wheat, milk, as well as E. coli lysate, and
1 mg/ml for B. fragilis lysate. For the measurement of background
binding, plates without coated antigens were used. All following
steps were performed at room temperature unless stated differ-
ently. Reagents, sera and fecal lysates were diluted in PBS/bovine
serum albumin (BSA) 1%. Between all following steps, microtitre
plates were washed four times with 200 ml of PBS/BSA 0.1%/
TWEEN 0.05% using an ELISA washer (Nunc). Plates were
blocked with 200 ml PBS/BSA 5% for 1 h. In a next step, plates
coated with bacterial lysates were incubated with 50 ml avidin/
biotin blocking reagent (Vector laboratories) for 30 min to prevent
non-specific streptavidin binding. Subsequently, different dilutions
of 50 ml serum or fecal homogenates were added in duplicates
(serum IgG: 1:400, 1:1.600, and 1:6.400; serum IgA: 1:100 and
1:800; stool IgG and IgA: 1:35 final dilution [1:5 pre-dilution as
described above and 1:7 further dilution]; higher dilutions for sera
or feces if required). A 2-fold serial dilution curve of a serum with
known high reactivity for the respective antigen served as
standard. Serum and standard were incubated overnight at 4uC.
The following incubation steps were: 100 ml of H2O2 for 10 min
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for blocking of endogenous peroxidases (only in plates coated with
bacterial lysates), 50 ml anti-human IgG (100 ng/ml; BD Phar-
mingen; Clone G18-145) or anti-human IgA (500 ng/ml; BD
Pharmingen; Clone G20-359) for 2 h; 50 ml streptavidin-horse-
radish peroxidase solution (R&D Systems) for 40 min; 100 ml
TMB (3,39 – 5,59-Tetramethylbenzidin; Sigma) substrate solution
(1 mg/ml in 0.05 M phosphate-citrate buffer, pH 5.0) for 10–
15 min. The reaction was stopped by adding 50 ml 2N H2SO4.
Optical density was read photometrically at 450 nm.
Total fecal IgG and IgA were measured in 1:50 and 1:1000
diluted fecal homogenates with commercially available ELISA kits
according to manufacturer’s instructions (eBioscience).
Analyses and statistics
Specific IgG and IgA levels in serum and feces are expressed as
arbitrary units (AU). The AU assigned to the standard serum were
defined by the dilution at which the OD was at least two times
higher than the background OD of the buffer control (dilution =
AU). The three times standard deviation (SD) of at least 10
independent background measurements was always below two
times of the background OD level. The two times background OD
was also set as the detection limit. For analysis, background OD
levels of the respective samples or standards measured on plates
without coating of specific antigens (only blocking with BSA) were
substracted from the ODs of the antigen-specific measurement.
Samples were analysed at different dilutions (see above). The OD
of the highest dilution above the detection limit was used for
calculation of the AU. The calculated AU was corrected by the
dilution factor. If all measurements were above the upper limit of
detection, measurements of higher dilutions were performed.
Serum values are represented as median. Boxes and whiskers
represent 25/75 percentiles and 10/90 percentiles, respectively.
Statistical significance was analysed by the Mann Whitney U test
for the comparison of two groups and by the Kruskal-Wallis test
followed by a Dunn’s post hoc test for the comparison of multiple
groups. Correlations were analyzed by the Spearman correlation
test.
Since specific antibodies were only detectable in less than 50%
of the samples, the results are represented as percentage of
measurements above the detection limit followed by a Chi-square
test. In order to have a quantitative analysis, results are
additionally represented as geometric means 6 95% confidential
interval followed by statistical significance analysis using the
Kruskal-Wallis test and Dunn’s post hoc test.
Statistical analyses were performed using SPSS and GraphPad
Prism.
Results
Anti-food and anti-microbial IgG and IgA in serum
IgG and IgA Abs specific for ovalbumin, wheat, milk, S.
cerevisiae-derived mannan, E. coli lysate, and B. fragilis lysate
were quantified by ELISA in the serum of patients suffering from
CD, UC, patients with non-IBD acute gastroenteritis/colitis
(AGE) as well as age-matched controls without inflammation in
the gastrointestinal tract. IgG and IgA Abs specific for all six
antigens were detectable in the majority of patients and controls,
although there was a high variation in the amount of detectable
Abs (Figure 1). ASCA and anti-B. fragilis IgG and IgA levels were
significantly increased in CD patients while specific IgG and IgA
for ovalbumin, wheat, milk, and E. coli showed no significant
differences within the patient groups and controls (Figure 1).
There was a strong correlation (rs=0.48–0.73) between levels of
IgG directed against different food antigens within single
individuals while the correlation between different anti-microbial
IgG or between anti-food and anti-microbial IgG was generally
lower (Figure F1A). For IgA, the correlation between different Ab
levels within single individuals was in most cases between 0.2 and
0.6 regardless of their specificity (Figure S1B). The correlation
between IgG and IgA levels for the same antigen was low and not
significant for ovalbumin and wheat, whereas generally stronger
correlation rates could be found for milk, ASCA, E. coli, and B.
fragilis (Figure S1C).
Anti-food and anti-microbial serum IgG and IgA in
patient subgroups
Anti-food IgG, but not anti-microbial IgG, correlated negatively
with the age of controls and patients (rs=20.15–20.5), while most
specific IgA tended to correlate positively with the age of
individuals (rs=0.34–0.61) (Figure S2).
CD patients with stricturing and/or penetrating (fistulas,
abscesses) disease displayed significantly higher amounts of anti-
E. coli and anti-B. fragilis IgA than non-stricturing/penetrating
CD patients, and higher amounts of anti-B. fragilis IgG and IgA
than controls (Figure2). Interestingly, stricturing/penetrating CD
patients also had significantly higher levels of anti-ovalbumin and
anti-wheat IgA than non-stricturing/penetrating CD patients or
controls while, conversely, arthropathy was associated with
significantly decreased levels of anti-ovalbumin and anti-wheat
IgG (Figure 3). Significantly decreased levels of anti-ovalbumin
and anti-milk IgG were also observed in UC patients with
arthropathy (Figure S3).
Anti-TNF-a treatment in CD patients was associated with
decreased levels of ASCA IgG and IgA as well as anti-E. coli IgG,
whereas anti-food and anti-B. fragilis IgG and IgA levels were not
different in anti-TNF-a treated patients (Figure 4). The duration
of anti-TNF-a treatment was 13610 months (mean 6 SD,
n= 15). The indication was steroid-dependent/-refractory inflam-
matory activity that could not be sufficiently treated with
immunosuppressants (n = 10), fistulas (n = 3), post-surgery prophy-
laxis (n = 1) and CD-associated granulomatous chelitis (n = 1).
In our analysis the following parameters were not significantly
associated with the Ab levels measured in this study: age at disease
onset, disease location, history of surgery, clinical disease activity
scores (HBS for CD and CAI for UC), serum CRP levels, WBC,
ESR, presence of food intolerance, treatment with steroids or
immunosuppressants. Consistent with the fact that specific Ab
levels are independent of the clinical disease activity, the amount
of anti-food and anti-microbial Abs found in serum were relatively
stable over time in patients investigated at different time points
(Figure S4).
Anti-food and anti-microbial IgG and IgA in feces
Concentrations of total fecal IgA were about 1000 times higher
than concentrations of fecal IgG which were below the detection
limit in about 30% of the cases (Figure S5). Concentrations of fecal
IgG and IgA were not significantly different between controls and
patient groups, although IgA levels tended to be higher in patient
groups.
Specific fecal IgG were only detectable in 0–28% of controls,
whereas the percentage of samples above the detection limit and
the geometric means of absolute values were generally higher in
CD and AGE patients for all tested antigens (Figure 5A/B). UC
patients had similar amounts of fecal specific IgG levels compared
to controls with only a slight but not significant increase in anti-E.
coli IgG levels. The highest levels of specific anti-food and anti-
microbial IgA were found in controls and AGE patients (Figure 5
C/D). CD patients had lower levels of specific IgA for all tested
Serum and Fecal Anti-Food and Anti-Microbial Abs in IBD
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Figure 1. Serum IgG and IgA levels specific for food and microbial antigens in IBD patients and controls. Serum IgG (A–F) and IgA (G–L)
specific for ovalbumin (A/G), wheat (B/H), milk (C/I), mannan from S. cerevisiae = ASCA (D/J), and lysates from E. coli K12 (E/K) and B. fragilis ATCC
25285 (F/L) were quantified by ELISA in control patients/healthy controls (Con; n = 61) and patients suffering from CD (n = 52), UC (n = 29) and acute
gastroenteritis/colitis (AGE; n = 12). Each dot represents one patient. Medians with interquartile ranges are indicated. P values (*,0.05; **,0.01; ***,
0.001) were determined by Kruskal-Wallis test followed by a Dunn’s post hoc test.
doi:10.1371/journal.pone.0106750.g001
Figure 2. Anti-food and anti-microbial serum IgG and IgA levels in CD patients with or without stricturing/penetrating disease and
controls. Specific serum IgG (A) and IgA (B) were quantified by ELISA in control patients/healthy controls (n = 61) and CD patients without (n = 17)
and with (n = 34) stricturing and/or penetrating complications. Boxes indicate median and 25/75 percentiles and whiskers indicate 10/90 percentiles.
P values were determined by Kruskal-Wallis test followed by a Dunn’s post hoc test (*,0.05; **,0.01; ***,0.001) or by Mann Whitney U test (# ,
0.05). Mann Whitney U test was only applied between CD subgroups and results are only shown if the Dunn’s post hoc test did not show any
significance.
doi:10.1371/journal.pone.0106750.g002
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antigens except for ASCA although the differences did not reach
statistical significance in the post-hoc test. The lowest IgA levels for
all antigens were found in UC patients. The overall results were
statistically different in the Kruskal-Wallis analysis for the three
anti-food and anti-B. fragilis IgA, whereas the results for
ovalbumin and wheat were only significantly different between
controls and UC patients in the post-hoc analysis.
There was no statistical significant correlation between serum
and fecal Ab levels in controls and UC patients. In CD patients we
found a positive correlation between serum and fecal Ab levels for
all anti-food IgGs and IgAs, except for anti-ovalbumin IgA (Figure
S6).
Discussion
Immune tolerance towards luminal antigens is a key regulatory
mechanism to maintain the homeostasis at the intestinal mucosal
surface. Innate and adaptive immune responses towards com-
mensals have been suggested to play a role in triggering chronic
inflammation in IBD [24], which is associated with a breakdown
of immune tolerance. A number of IBD patients suffer from food
intolerances showing an improvement of well-being by avoiding
special nutritive components [25–27]. However, the relevance of
the relation between an exaggerated immune response against
food antigens and the occurrence of food intolerance in IBD
patients remains an open question.
In the present study we analysed in parallel serum and fecal Abs
specific for dietary and microbial antigens in a cohort of IBD
patients and controls (for summary of the results see table 1). The
objective of this study was to investigate whether increased local or
systemic levels of anti-microbial Abs in IBD patients correlate with
levels of anti-food Abs, which would argue for a general loss of
immune tolerance towards luminal antigens. However, our results
reveal that on the systemic level only Abs directed against some
microbial antigens are elevated in CD but not UC patients,
whereas anti-food Abs showed no general alterations in IBD
patients. Anti-food IgA levels were slightly elevated in CD patients
with a stricturing/penetrating phenotype. These patients have also
elevated anti-microbial Abs levels, a finding that confirms the
results of several former studies [6,10,28,29]. Altogether, these
findings argue for a more general loss of tolerance to intestinal
antigens in severely affected CD patients that very likely have a
stronger disturbance of the intestinal barrier than CD patients
without stricturing and penetrating lesions. Those patients
generally have a milder disease course and/or shorter disease
duration and only show enhanced Ab levels towards selected
microbial antigens.
Surprisingly, anti-food IgG levels were decreased in CD and
UC patients with arthropathy, an extraintestinal manifestation of
IBD which occurs in about 30% of patients. The reason for these
findings remains completely elusive and requires further investi-
gation. One recent study demonstrates higher anti-food Ab levels
in jejunal fluids of patients with rheumatoid arthritis [30], however
we are not aware of further studies analysing antibodies directed
against food antigens in patients with arthritis or arthropathy.
Figure 3. Anti-food and anti-microbial serum IgG and IgA levels in CD patients with or without arthropathy and controls. Specific
serum IgG (A) and IgA (B) were quantified by ELISA in control patients/healthy controls (n = 61) and CD patients without (n = 39) and with (n = 12)
current arthropathy. Boxes indicate median and 25/75 percentiles and whiskers indicate 10/90 percentiles. P values were determined by Kruskal-
Wallis test followed by a Dunn’s post hoc test (*,0.05; **,0.01; ***,0.001).
doi:10.1371/journal.pone.0106750.g003
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Biologicals targeting TNFa are currently the most effective
treatment for IBD. We found lower levels of anti-microbial Abs in
CD patients receiving anti-TNFa treatment compared to CD
patients that did not receive anti-TNFa treatment. The Ab levels
in patients on anti-TNFa treatment were almost in the range of
healthy controls. We may interpret this finding with caution
because our results do not include longitudinal data from patients
before and after introduction of anti-TNFa treatment and because
our cohort of anti-TNFa CD patients is relatively small and
includes only 15 cases. Furthermore, a recent study that included
longitudinal sampling did not report a decrease in ASCA levels in
CD patients after introducing anti-TNFa [31]. However, in the
latter study only in 12 out of 45 CD patients ASCA antibodies
could be detected. If anti-TNFa treatment affect anti-microbial Ab
levels, it is unlikely to be solely explained by the effects of this
treatment on dampening active disease and acute inflammation
since Ab levels were independent of clinical disease activity scores
and inflammatory markers. However, anti-TNFa therapy is most
effective in the induction of long term remission and mucosal
healing. It is clearly conceivable that a long-term suppression of
intestinal inflammation and repair of intestinal barrier defects may
lead to decreased anti-microbial adaptive immune responses
including ASCA levels. In line with this hypothesis it is important
to note that Gluten-free diet has been shown to reduce ASCA
levels in patients with celiac disease in which ASCA levels are also
slightly increased [32]. Other mechansims such as direct targeting
of memory T and B lymphocytes by anti-TNFa Abs may also play
a role in reduction of ASCA levels. It would be interesting to
confirm our results in larger cohorts including longitudinal
samples and to further decipher the underlying mechanisms.
Fecal and serum Ab levels did not correlate in controls and UC
patients, whereas higher correlations were detected in CD patients
in particular for anti-food Abs. On the one hand, fecal Ab levels
showed specific patterns in different patient groups with enhanced
specific IgG against all antigens in patients with CD and acute
gastroenteritis or colitis. On the other hand, specific IgA levels
against all antigens were significantly decreased in UC patients.
Fecal Ab levels were frequently not detectable or only just above
the detection limit. There might be several reasons for the low
specific Ab levels in fecal samples including the fact that the
majority of fecal IgGs may be degraded or bound to commensals
as it has been reported recently [33]. However, our results are
consistent with previous reports showing similar patterns for
different microbial Ab levels in mucosal washings obtained during
endoscopy [11,34]. It is unclear whether increased specific fecal
IgG levels mainly seen in patients with CD and AGE result from
higher local production or serum leakage. However, higher local
production of anti-microbial Abs has been strongly suggested by
the study of Macpherson et al., since they did not find elevated
fecal IgG levels directed against bacterial strains exclusively found
on the skin flora [11]. It is unlikely that decreased specific IgA
levels in UC patients are caused by higher fluid contents in the
stool, since total IgA levels are slightly elevated and we did not find
any correlation between specific fecal IgA and disease activity.
Figure 4. Anti-food and anti-microbial serum IgG and IgA levels in CD patients with or without anti-TNFa treatment and controls.
Specific serum IgG (A) and IgA (B) were quantified by ELISA in control patients/healthy controls (n = 61) as well as in CD patients without (n = 17) and
with (n = 34) current anti-TNFa treatment. Boxes indicate median and 25/75 percentiles and whiskers indicate 10/90 percentiles. P values were
determined by Kruskal-Wallis test followed by a Dunn’s post hoc test (*,0.05; **,0.01; ***,0.001) or by Mann Whitney U test (# ,0.05). Mann
Whitney U test was only applied between CD subgroups and results are only shown if the Dunn’s post hoc test did not show any significance.
doi:10.1371/journal.pone.0106750.g004
Serum and Fecal Anti-Food and Anti-Microbial Abs in IBD
PLOS ONE | www.plosone.org 6 September 2014 | Volume 9 | Issue 9 | e106750
Furthermore, the fact that total fecal IgG and IgA levels did not
significantly differ among controls and patient groups whereas we
found significant differences in Abs specific for luminal antigens
further argues for disease-specific patterns of Ab-production rather
than non-specific common mechanisms for up- and down-
regulation of IgGs and IgAs. The underlying mechanism and
functional consequence of our results are unclear. However, it is
interesting to note that CD is associated with increased specific
IgGs, which are supposed to have proinflammatory functions and
are primed exclusively by T cell-dependent mechanisms, whereas
UC is associated with decreased specific IgA production, which
may have anti-inflammatory functions due to immune exclusion.
Overall, the profile of systemic and local Abs specific for
microbial and food antigens reveals a complex picture. Different
patient groups and controls showed a distinct Ab pattern, which
argues for the fact that adaptive immune responses towards
luminal antigens play a distinct role in these diseases. However, the
results show that the simple assumption that gut inflammation and
barrier defects cause higher IgG and IgA production against
luminal antigens is wrong. The results of this and other studies
raise several questions. For example, it remains not fully
understood why Ab production towards distinct microbial and
food antigens is differentially regulated, and why CD patients have
elevated serum reactivity towards multiple microbial antigens
[6,29], whereas this phenomenon seems to be less obvious for UC
patients, although the microbial load is much higher in the colon
[8]. We may speculate that the association of microbial antigens
with immune-stimulating molecules such as lipopolysaccharides
and peptidoglycans have a major influence on their potential to
induce adaptive immune responses. Furthermore, lymphoid
aggregates are more frequently found in the small intestine than
in the colon. This fact might be one reason for increased Ab
production against luminal antigens in CD patients that often
show small intestinal and transmural involvement, whereas this is
Figure 5. Fecal IgG and IgA levels specific for food and microbial antigens in IBD patients and controls. Specific fecal IgG (A/B) and IgA
(C/D) were quantified by ELISA in control patients/healthy controls (Con; n = 39) and patients suffering from CD (n= 20), UC (n = 17) and acute
gastroenteritis/colitis (AGE; n = 9). (A/C) Percentage of measurements above the detection limit and (B/D) geometric means 6 95% confidential
interval are shown. (A/C) P values (*,0.05; **,0.01) were determined by Chi-square test. (B/D) P values (*,0.05; **,0.01; ***,0.001) were
determined by Kruskal-Wallis test followed by a Dunn’s post hoc test. The results of the Kruskal-Wallis test are indicated above the graph and the
results of the Dunn’s post hoc test are indicated directly above the bars.
doi:10.1371/journal.pone.0106750.g005
Table 1. Summary of results. Ab levels compared to controls.
Crohn’s disease Ulcerative colitis
Serum anti-food IgG/IgA « 1,2 « 2
Serum anti-microbial IgG/IgA q 3,4 «
Fecal anti-food/-microbial IgG q «
Fecal anti-food/-microbial IgA « Q
1Slightly increased anti-food IgA levels in CD patients with a structuring/penetrating phenotype.
2Decreased anti-food IgG levels in CD and UC patients with artopathy.
3Only some microbial antigens.
4Patients receiving anti-TNFa treatment have lower Ab levels.
doi:10.1371/journal.pone.0106750.t001
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not the case for colonic inflammation restricted to the mucosa as
found in UC patients.
One important finding of our study is that we did not find any
correlation between food-specific Ab levels and clinical symptoms.
Our data does not support the idea that measurements of anti-food
specific IgG or IgA is of any clinical relevance for patients suffering
from CD or UC. In particular, it does not predict the presence of
food intolerance. It is also unclear whether anti-microbial Abs
have any disease-aggravating effect or whether they are only a
concomitant phenomenon of chronic gut inflammation. Since we
found detectable Ab levels in many individuals it is even
questionable whether high Ab levels are associated with a loss of
tolerance. Furthermore, some of the measured Abs might be cross-
reacting Abs that were primarily formed against other antigens.
For example it has been shown that ASCA do cross-react with
Candida antigens [35] and that ASCA levels do not correlate with
the presence of S. cervisiae in the intestinal tract of patients [36].
Acute exacerbation of disease does not correlate with antibody
levels, however enhanced ASCA and other anti-microbial Ab
levels correlate with more complicated disease courses and anti-
TNF-a therapy, It has been shown that microbial-specific IgA
mediates gut homeostasis in animal models [37] and might
therefore have anti-inflammatory functions in IBD. However, it
has been reported microbial-antigen specific T cells have been
shown to induce chronic gut inflammation in experimental models
[38,39], which provides some evidence that a loss of adaptive
immune tolerance towards microbial antigens can exaggerate
chronic intestinal inflammation.
In summary, our study reveals that CD, UC and AGE patients
as well as non-inflammatory controls have distinct patterns of IgG
and IgA against food and microbial antigens in serum and feces
suggesting differentially regulated immune responses towards
intestinal antigens. However, food-specific Abs have not yet been
proven to be a valuable biomarker for IBD or food intolerance.
Supporting Information
Figure S1 Correlation of specific serum IgG and IgA
levels. Correlation of serum IgG (A) and serum IgA (B) levels
specific for different food and microbial antigens in single
individuals. Correlation of serum IgG and IgA levels against the
same antigen (C). Y axis indicates Spearmen’s correlation
coefficient rs. Correlations are shown separately for control
patients/healthy controls (Con; n = 61) and patients suffering
from CD (n= 52) and UC (n= 29). Ova, ovalbumin; Mi, Milk;
Wh, wheat; ASCA, anti-Saccharomyces cerevisiae antibodies; EC,
Escherichia coli; Bac, Bacteroides fragilis. Significances are
indicated above bars (*,0.05; **,0.01; ***,0.001).
(TIF)
Figure S2 Correlation of age and specific serum IgG
and IgA levels. Correlation of serum IgG and serum IgA levels
specific for different food and microbial antigens and age of
patients and controls. Correlations are shown separately for
control patients/healthy controls (Con; n= 61) and patients
suffering from CD (n= 52) and UC (n= 29). Significances are
indicated above bars (*,0.05; **,0.01; ***,0.001).
(TIF)
Figure S3 Anti-food and anti-microbial serum IgG and
IgA levels in UC patients with or without arthropathy
and controls. Specific serum IgG (A) and IgA (B) were
quantified by ELISA in control patients/healthy controls (n = 61)
and UC patients without (n = 20) and with (n = 9) current
arthropathy. Boxes indicating median and 25/75 percentiles and
whiskers indicating 10/90 percentiles are shown. Kruskal-Wallis
test did not show any significant difference between the three
groups. Mann Whitney U test was applied between UC subgroups
(#,0.05).
(TIF)
Figure S4 Specific serum IgG and IgA levels in IBD
patients at different time points. Anti-food and anti-
microbial serum IgG (A) and IgA (B) were measured in 11 CD
and 6 UC patients at two different visits (91644 days between the
two visits, mean 6 SD). rs indicates Spearman’s correlation
coefficient between the two measurements.
(TIF)
Figure S5 Total fecal IgG and IgA levels in IBD patients
and controls. Total IgG (A) and IgA (B) in fecal homogenates
were quantified by ELISA in control patients/healthy controls
(Con; n = 39) and patients suffering from CD (n= 20), UC (n= 17)
or acute gastroenteritis/colitis (AGE; n= 9). Geometric means 6
95% confidential intervals are shown.
(TIF)
Figure S6 Correlation of serum vs. fecal antigen-
specific IgG and IgA levels. Correlations are shown separately
for control patients/healthy controls (Con; n= 39) and patients
suffering from CD (n= 20) and UC (n= 17). Significances are
indicated above bars (*,0.05; **,0.01).
(TIF)
Table S1 Patient characteristics.
(DOCX)
Table S2 Detailed characteristics of IBD patients.
(DOCX)
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